ESC 365 - When should we start P2Y12 inhibitors in patients with an acute coronary syndrome?

ESC Premium Access

When should we start P2Y12 inhibitors in patients with an acute coronary syndrome?

Session: Starting, stopping, and everything in between: recent data concerning dual antiplatelet therapy in ACS

Topic: Thrombosis and platelets

Speaker: Professor G. Montalescot (Paris, FR)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Gilles Montalescot

Pitie Salpetriere APHP University Hospital, Paris (France)

35 presentations

1 follower

3 more presentations in this session

Role of intravenous antiplatelet drugs in acute coronary syndromes

Speaker: Professor D. Angiolillo (Jacksonville, US)

How to manage ACS patients who require oral anticoagulation?

Speaker: Professor J. ten Berg (Nieuwegein, NL)

How long is long enough? When to stop DAPT after an acute coronary syndrome?

Speaker: Doctor L. Mauri (Boston, US)

Access the full session

Starting, stopping, and everything in between: recent data concerning dual antiplatelet therapy in ACS

Speakers: Professor G. Montalescot, Professor D. Angiolillo, Professor J. ten Berg, Doctor L. Mauri

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources